Bioactivity analysis of novel indole derivatives on hepatocellular carcinoma as sirtuin inhibitors

2021-9-8
Bınarcı, Büşra
Hepatocellular carcinoma is ruthless cancer, a subtype of primary liver cancer and affects many people with various ethnic backgrounds and age intervals. Indole derivative molecules are potent chemicals used in several drugs and target many essential proteins malfunctioning multiple diseases. One of the targets of indole derivatives is histone deacetylases (HDACs), which reverses histone acetylation modifications that open DNA to lead transcription machinery to promote transcription. This study screened 28 novel indole derivatives for their cytotoxicity capacity against three different cancer types. Four of them were selected based on the inhibitory concentration 50 (IC50) values and structure-activity relations. Then, their targets were investigated with the DEEPScreen database and with molecular docking studies. In silico studies predicted that the molecules might interact with Sirt1, which is class III HDAC. For in vitro validation, the nuclear fraction of HCC cells was used in Sirtuin enzymatic activity assays. After the validation, one of the most critical targets of Sirt1, p53, which is also a vital tumor suppressor and mutagenized in HCC, was investigated. As a possible mechanism of action of the compounds, they could increase the acetyl-p53 level by blocking Sirt1 and lead p53- derived G1-mediated apoptosis in HCC cells.

Suggestions

Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Hawash, Mohammed M. A.; Kahraman, Deniz Cansen; Eren, Fikriye; Atalay, Rengül; BAYTAŞ, Sultan (2017-03-31)
Despite having the second highest mortality associated with cancer, currently Sorafenib is the only FDA-approved chemotherapeutic agent available for liver cancer patients which can only improve survival for few months. In this study, various pyrazolic chalcone analogous compounds were synthesized and evaluated as potential chemotherapeutic agents for the treatment of hepatocellular carcinoma (HCC). Modifying the central pyrazole ring at the C(3)-position with different heteroaryl rings and substituting the...
Analyses and modeling of ovarian cancer microarray data
Karakelle, Barış S; Purutçuoğlu Gazi, Vilda; Department of Biomedical Engineering (2019)
Ovarian cancer is one of the common cancer types among other oncological diseases. The major causes of this cancer can be listed as age, obesity, hormone therapy, material inheritance and contraceptive pills. Due to its generality and importance, many researches have been conducted from distinct labs about this illness and its plausible causes have been intensively investigated either inmicroarray studies, where just part of the related genes are detected, or in thepairwise correlation analyses between the ...
Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines
Hawash, Mohammed; Kahraman, Deniz Cansen; Ergun, Sezen Guntekin; Cetin-Atalay, Rengul; BAYTAŞ, SULTAN (2021-12-01)
Background Liver cancer is predicted to be the sixth most diagnosed cancer globally and fourth leading cause of cancer deaths. In this study, a series of indole-3-isoxazole-5-carboxamide derivatives were designed, synthesized, and evaluated for their anticancer activities. The chemical structures of these of final compounds and intermediates were characterized by using IR, HRMS, H-1-NMR and C-13-NMR spectroscopy and element analysis. Results The cytotoxic activity was performed against Huh7, MCF7 and HCT116...
Network-based discovery of molecular targeted agent treatments in hepatocellular carcinoma
Fayetörbay, Rumeys; Tunçbağ, Nurcan; Department of Bioinformatics (2020)
Hepatocellular carcinoma (HCC) is one of the most-deadly cancers and the most common type of primary liver cancer. Multikinase inhibitor Sorafenib is one of FDA approved targeted agents in HCC treatment. PI3K/AKT/mTOR pathway is altered in about 51% of HCC; hence, understanding how Sorafenib and PI3K/AKT/mTOR pathway inhibitors act at signaling level is crucial for targeted therapies and to reveal the off-target effects. In this work, we use gene expression profiles (GEPs) of HCC cells (Huh7 and Mahlavu) wh...
Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer
TASKOPARAN, Betul; SEZA, Esin Gulce; Demirkol, Secil; TUNCER, Sinem; Stefek, Milan; Gure, Ali Osmay; Banerjee, Sreeparna (2017-12-01)
Aldo-keto reductases (including AKR1B1 and AKR1B10) constitute a family of oxidoreductases that have been implicated in the pathophysiology of diabetes and cancer, including colorectal cancer (CRC). Available data indicate that, despite their similarities in structure and enzymatic functions, their roles in CRC may be divergent. Here, we aimed to determine the expression and functional implications of AKR1B1 and AKR1B10 in CRC.
Citation Formats
B. Bınarcı, “Bioactivity analysis of novel indole derivatives on hepatocellular carcinoma as sirtuin inhibitors,” M.S. - Master of Science, Middle East Technical University, 2021.